UC Davis Trainee Selected for Presentation at the ACTS
Marcus Deloney, a trainee in the UC Davis TL1 training program, was selected at one of the six presenters at the recent Association for Clinical and Translational Science (ACTS) virtual meeting. With over 500 abstracts submitted, selection for presentation represents the top 1%.
His research focuses on the use of biologically derived therapeutics to prevent the progression of osteoarthritis. These biopharmaceutics are subject to enzymatic degradation which negates their usefulness, therefore we have developed thermoresponsive, hollow, degradable nanoparticles to protect them from enzymatic degradation. The nanoparticles encapsulate the biopharmaceutical and ensure its targeted delivery into the joint space of the knee to treat and prevent the progression of osteoarthritis.
Mr. Deloney is a PhD candidate at the University of California, Davis and received his MSE in Chemical Engineering from the University of Michigan in 2016.
The TL1 program is jointly sponsored by the UC Davis School of Medicine and the Clinical and Translational Science Center (CTSC). It provides clinical and translational research training for medical students, predoctoral students and postdoctoral scholars in the basic sciences using a team science approach. This program is part of the fully integrated approach of the UC Davis CTSC to advance education and career development by early identification, recruitment, and training of a critical mass of multidisciplinary, clinical and translational investigators working to improve human health.